Cyclosporine (CYA) and tacrolimus (TAC) are calcineurin inhibitors with similar action mechanisms. However, there have not been any detailed reports on the pharmacokinetic differences of relationship among are under the concentration time curve (AUC), peak concentration (C p ), and trough concentration (C t ), regarding CYA and TAC after oral administration in a controlled group. 1) AUC of CYA has been reported to be associated with clinical efficacy. [2] [3] [4] [5] On the other hand, the relationship between AUC of TAC and the clinical efficacy of TAC has not been evaluated precisely. However, it is generally thought that AUC is the most reliable pharmacokinetic parameter to predict the clinical efficacy of calcineurin inhibitors including TAC. CYA blood concentration is often monitored by blood concentration at 2 h after administration (C 2 ) to be more significantly associated with AUC, 6) and TAC blood concentration is monitored by C t . It has yet to be explained why only AUC of CYA correlates more significantly with C 2 , and we could not clearly account for why the monitoring timings differ between CYA and TAC. Therefore, we investigated this issue to compare the blood concentration curve patterns and pharmacokinetic parameters of CYA and TAC in renal transplant recipients by using new pharmacokinetic parameters such as area under the trough level (AUTL) and area above the trough level (AATL). These parameters are parts of AUC and are dependent on C t and C p , respectively as described later.
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MATERIALS AND METHODS

Patients
Twelve hours of monitoring of CYA and TAC blood concentrations was performed on 20 patients who were administered a CYA microemulsion formulation at 41.8Ϯ 20.5 (meanϮS.D.) d after renal transplantation and on 24 patients who were administered TAC at 41.4Ϯ21.4 d after transplantation. This monitoring was routinely carried out once before hospital discharge. The CYA-administrated patients consisted of 11 males and 9 females aged 42.7Ϯ1.0 (meanϮS.D.) years, and the mean (S.D.) body weight of these patients was 53.5Ϯ10.0 kg. The TAC-administrated patients consisted of 15 males and 9 females aged 46.5Ϯ11.3 years, and their mean body weight was 52.3Ϯ9.9 kg ( Table  1) . None of the patients had digestive or liver dysfunction, which may affect the absorption or metabolism of CYA or TAC. All patients received a triple immunosuppressive-drug regimen, which consisted of calcineurin inhibitors (CYA or TAC), methylprednisolone, and either mycophenolate mofetil or azathioprine. Other drugs known to affect the pharmacokinetics of CYA or TAC were not administered to these patients. Informed consent was obtained from all patients included in this study. The pharmacokinetic parameters for CYA and TAC were evaluated. We devised AUTL and AATL as new pharmacokinetic parameters (Fig. 1) . AUTL was calculated from the area under the line between the C t just before administration (hour 0) and C t just before the next administration (hour 12). AATL was calculated to subtract AUTL from AUC. The correlation coefficients between AUTL and AATL versus AUC were analyzed to verify whether AUTL, namely C t is more conducible to the area in AUC, or AATL, namely C p in CYA and TAC, respectively. Then the AUTL/AUC%, a ratio accounting for AUTL in AUC, was estimated. AUTL/AUC% would be a new parameter that can represent the relationship between AUC and C t or C p . The ratio of C p and C t (C p /C t ), AUC per dose (D) per body weight (BW) (AUC/D/BW), C p /D/BW and C t /D/BW were also compared between the CYA-and TAC-treated recipients, alike.
Evidence of Different Pharmacokinetics
Statistics We used two-tailed unpaired t-tests and variance analysis for comparisons of mean ages, body weights, mean days after transplantation, and the mean pharmacokinetic parameters between the CYA-and TAC-treated recipients. Fisher's exact probability tests were used to compare the proportion of males and females between the two recipient groups. Pearson's correlation coefficients were used to show correlation coefficients between AUTL and AATL versus AUC in CYA-and TAC-treated recipients. These analyses were performed with Statview. 7) In each case, two-sided p values less than 0.05 were considered to be significant.
RESULTS
The pharmacokinetic parameters of calcineurin inhibitors were compared between the 20 CYA-treated recipients and 24 TAC-treated recipients. There was no significant difference in the basic profiles including age, gender, period after transplantation, and BW between CYA-and TAC-treated recipients. D/BW were 2.27Ϯ0.82 mg/kg in the CYA group, and 0.09Ϯ0.05 mg/kg in the TAC group (Table 1) . AUTL/ AUC (%), C p /C t , AUC/D/BW, C p /D/BW, and C t /D/BW in CYA and TAC groups are shown in Table 2 . Mean (S.D.) of AUTL/AUC% for TAC was 73.4 (8.1), which was significantly larger than that of CYA (41.9Ϯ6.9%, pϽ0.0001) (Fig.  2) . C p /C t of TAC was 1.93 (0.43), which was significantly lower than that of CYA (6.00Ϯ1.78, pϽ0.0001). As AUC/D/ BW values for CYA and TAC were almost similar, the ratio of AUC/D/BW between CYA and TAC (CYA/TAC of AUC/ D/BW) was 0.92. C p /D/BW (ng/ml)/(mg/kg) of CYA was 433.1 (90.3), which was significantly higher than that of TAC (292.6Ϯ135.7, pϽ0.005). The ratio of the value of C p /D/BW between CYA and TAC was 1.48. However, C t /D/BW of CYA was 77.1Ϯ23.6 (ng/ml)/(mg/kg), which was significantly lower than that of TAC (160.0Ϯ91.8, pϽ0.005), and the ratio of C t /D/BW between CYA and TAC was 0.48.
Individual blood-concentration time curves of CYA and TAC are shown in Fig. 3 . As shown in Fig. 4 , the mean blood-concentration time curve of the two calcineurin inhibitors revealed that the CYA curve showed a higher and sharper peak, and a lower trough, whereas the TAC curve showed a lower and gentler peak, and higher trough. AUTL/AUC% of CYA, to indicate the relationship among C p , C t , and AUC, was 41.9Ϯ6.9 (Fig. 2a) . On the contrary, AUTL/AUC% of TAC was 73.4Ϯ8.1 (Fig. 2b) .
The correlation coefficient with AUC of CYA was higher with AATL (r 2 ϭ0.9024; Fig. 5b ) than AUTL (r 2 ϭ0.7110; Fig. 5a ). Conversely, the correlation coefficient with AUC of TAC was higher with AUTL (r 2 ϭ0.9029; Fig. 5c ) than AATL (r 2 ϭ0.7123; Fig. 5d ).
DISCUSSION
The immunosuppressive action mechanisms of CYA and TAC are almost the same except for a difference in their binding proteins; i.e., cyclophilin for CYA and FK-binding protein (FKBP) for TAC. AUC of CYA is generally thought the most reliable pharmacokinetic parameter for the evaluation of its clinical efficacy. [2] [3] [4] [5] Therefore, CYA blood concentration is monitored by AUC for 0 to 4 h after administration (AUC 0-4 ) in many institutions after the use of CYA microemulsion formulation. 5) Alternatively, monitoring was also carried out by C 2 level, which is reported to correlate most closely with AUC as a simple monitoring method. the other hand, AUC of TAC is generally thought the most reliable pharmacokinetic parameter to predict the clinical efficacy as well as CYA, though the relationship between AUC of TAC and the clinical efficacy of TAC has not been evaluated precisely. Blood concentration of CYA is usually suggested to monitor by C 2 substituted for C p because AUC is more significantly correlated with C 2 than C t , 6) though TAC blood concentration is monitored by C t . However it has yet to be explained as to why only AUC of CYA correlates more significantly with C 2 than C t and we had been clearly unable to explain as to why the monitoring points differ between CYA and TAC, despite of the same calcineurin inhibitors. Therefore, we examined these issues by comparing the new pharmacokinetic parameters. We proved that the pharmacokinetic parameters were clearly different between CYA and TAC. Though CYA and TAC relatively gave almost the same bioavailability (AUC/D/BW), CYA had higher C p and a sharper blood concentration curve than TAC did. Though it was better known that CYA had a sharper blood concentration curve and TAC had a gentler curve, there have been no reports that AUC corrected by dose per body weight (AUC/D/BW), namely relative bioavailability was similar between CYA and TAC, and that C t of CYA was relatively lower than TAC, and that C p of CYA was higher. It is thought that there is a difference of pharmacokinetics between CYA and TAC, because the absorption rate constant of CYA is probably higher than that of TAC as CYA and TAC have almost the same half life.
It suggests an important problem that there is a distinct difference of blood concentration curve to have higher peak (C p is higher and C t is lower, relatively) like CYA, or the concentration curve not to make peak to keep minimum effective concentration (C p is lower and C t is higher, relatively) like TAC in effective and adverse reaction shown on Fig. 4 , even if same drugs have same values of AUC. The mono-pharmacokinetic parameters of only AUC are insoluble fundamentally. Pharmacokinetic analysis, including C t and C p , and not only AUC, will be required.
Furthermore, we used AUTL/AUC% as a new parameter being able to present the relationship among AUC, C p , and C t . It is important that these problems be solved to use AUTL/AUC%. Therefore, it was presumed that the AUC of CYA was largely dependent on C p , as the AUTL/AUC% was less than 50%. On the contrary, TAC gave lower C p and gentler blood concentration curves. As AUTL/AUC% of TAC was more than 70%, it was presumed that the AUC was largely dependent on C t , and the blood concentration curve was approximate to one of continuous intravenous infusion.
As described above, to confirm that AUC of CYA and TAC were dependent on C p and C t , respectively, we compared the correlation coefficients of AUTL and AATL versus AUC in both drugs. AUC of CYA was more significantly associated with AATL than AUTL (Figs. 5a, b) . Conversely, AUC of TAC was more significantly associated with AUTL (Figs.  5c, d ). We demonstrated that the degree of involvement of C p and C t in the area of AUC was different between CYA and TAC. We have prove that C 2 monitoring points for CYA, and C t monitoring points for TAC have been appropriate in this study, because the areas in AUC of CYA and TAC were significantly dependent on C p and C t , respectively. This result verified the difference of pharmacokinetics between CYA and TAC including the relationship among AUC, C p , and C t using similar clinical backgrounds in renal transplant patients.
Aside from this, the new parameter, AUTL has been also useful as follows; switching to continuous intravenous infusion from oral administration, and vice versa. Continuous infusion of CYA has been carried out more frequently in bonemarrow transplant recipients than renal transplants. Miller et al. 10) reported that the adjustment of CYA level to be 450-500 ng/ml by continuous infusion is well tolerated and effective in the prevention of acute graft-versus-host disease (GVHD). On the other hand, Ogawa et al. 11) reported that the incidence of acute GVHD in bone-marrow transplant recipients treated with continuous infusion of CYA with a target level to be 250-400 ng/ml was significantly higher than that in recipients treated with twice-daily infusions. We previously calculated a conversion value utilizing the ratio of AUTL (ϭAUCϪAATL) and AUC for predicting a target blood concentration when switched to continuous infusion from oral administration, 12) so that the target blood concentration of CYA administered by continuous infusion necessary was 2.55 times of C t by oral administration. The calculated CYA target level in continuous infusion corroborates the results of the CYA target level reported by Miller et al. 10) As described above, it is thought that the AUTL was useful when switched to continuous intravenous infusion from oral administration, and vice versa.
CONCLUSION
In conclusion, although there has never been a report given to account for the distinct differences in the pharmacokinetics between CYA and TAC including the association among AUC, C p , and C t , we clearly proved the differences in the pharmacokinetics between CYA and TAC in renal transplant recipients by using AUTL/AUC%, and we demonstrated with controlled clinical data why AUC of CYA correlated more significantly with C 2 , and why CYA blood concentration must be monitored by C p and why TAC blood concentration must be monitored by C t . We will further investigate the optimal pharmacokinetics of calcineurin inhibitors including the relationship among C p , C t , and AUC to investigate relationship between AUTL/AUC% and clinical efficacy.
A new pharmacokinetic parameter AUTL/AUC% should also be examined to investigate the difference of relationship between AUC, C p , and C t in many drugs. Pharmacokinetic analysis in the future will need to consider not only AUC separately, but also AUC including its relationships with C p and C t , when evaluating clinical efficacy and adverse reactions.
